Amphastar Pharmaceuticals, Inc. (AMPH) Gross margin 2016–2025
Amphastar Pharmaceuticals, Inc. (AMPH) gross margin by fiscal year — reported gross profit divided by reported revenue.
49.5%FY2025 · since FY2016: 40.8% → 49.5%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | 49.5% | -1.6 pp |
| FY2024 | 51.1% | -3.4 pp |
| FY2023 | 54.5% | +4.6 pp |
| FY2022 | 49.9% | +4.2 pp |
| FY2021 | 45.6% | +4.7 pp |
| FY2020 | 41.0% | +0.0 pp |
| FY2019 | 40.9% | +4.6 pp |
| FY2018 | 36.3% | -1.4 pp |
| FY2017 | 37.7% | -3.2 pp |
| FY2016 | 40.8% | — |
Gross margin = reported gross profit ÷ reported revenue for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice
More AMPH financial trends
AMPH RevenueAMPH Net incomeAMPH Net marginAMPH Gross profitAMPH Operating incomeAMPH Operating marginAMPH Operating cash flowAMPH Free cash flowAMPH Capital expendituresAMPH Return on equityAMPH Stock buybacksAMPH Dividends paidAMPH Total assetsAMPH Total liabilitiesAMPH Shareholders’ equityAMPH overview →